BEAM THERAPEUTICS INC (BEAM)
NASDAQ • Healthcare
$26.57
-$0.53 (-2.0%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About BEAM THERAPEUTICS INC
Name
BEAM THERAPEUTICS INC
CEO
John Evans
Website
Industry
Healthcare
Year Founded
2017
Employees
540
Beam Therapeutics Inc. develops gene-editing medicines in biotechnology, focused on precise genetic remedies for severe diseases. The company, which trades on NASDAQ as BEAM, recorded $139.7 million in revenue in FY2025. Its work centers on engineered therapies for blood disorders and other serious conditions, with operations based in the United States.
Fundamentals & Financials
Revenue (TTM)
$156M
Net Income (TTM)
-$85.4M
EPS (TTM)
-$0.82
ROA (TTM)
-6.16%
Current Ratio
14.57
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$26.57$26 - $26.93
52 Week RangeAvg. Volume$15.6 - $38.261.6M
Market Cap$2.7B
Peers & Related Assets
IBRXIMMUNITYBIO INC
$7.72-2.5%
COGTCOGENT BIOSCIENCES INC
$37.4-1.2%
DNLIDENALI THERAPEUTICS INC
$24.31-0.2%
RCUSARCUS BIOSCIENCES INC
$29.51-0.2%
IDYAIDEAYA BIOSCIENCES INC
$37.93+3.8%
MLYSMINERALYS THERAPEUTICS INC
$26.61+2.1%
ETNB89bio, Inc.
AGIOAGIOS PHARMACEUTICALS INC
GLPGGalapagos N.V.
RXRXRECURSION PHARMACEUTICALS INC CLAS